Company Depomed Inc Nasdaq

US2499081048

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	156	100.0 %	152	100.0 %	-2.67%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	156	100.0 %	152	100.0 %	-2.67%

Managers	Title	Age	Since
Heather Mason CEO	Chief Executive Officer	63	19-01-31
Ajay Patel DFI	Director of Finance/CFO	40	19-06-30
Howard Franklin CTO	Chief Tech/Sci/R&D Officer	-	23-03-05
William Iskos COO	Chief Operating Officer	-	21-07-31
Vanessa Fox PRN	Corporate Officer/Principal	-	18-04-30
Sam Schlessinger LAW	General Counsel	42	20-04-30
Paul Schwichtenberg PRN	Corporate Officer/Principal	53	18-03-31

Members of the board	Title	Age	Since
Peter Staple CHM	Chairman	72	03-10-31
James Tyree BRD	Director/Board Member	71	16-09-30
William McKee BRD	Director/Board Member	62	17-02-28
Heather Mason CEO	Chief Executive Officer	63	19-01-31
Jeffrey Vacirca BRD	Director/Board Member	55	23-07-30
Sravan Emany BRD	Director/Board Member	46	Nov. 13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	95,122,178	93,575,361 ( 98.37 %)	0	98.37 %

Name	Equities	%	Valuation
Nantahala Capital Management LLC 8.021 %	7,619,440	8.021 %	7 M $
BlackRock Advisors LLC 6.649 %	6,316,644	6.649 %	6 M $
Armistice Capital LLC 6.106 %	5,800,000	6.106 %	6 M $
Vanguard Fiduciary Trust Co. 5.136 %	4,878,543	5.136 %	5 M $
Michael Gorzynski 4.036 %	3,834,214	4.036 %	4 M $
Renaissance Technologies LLC 3.308 %	3,142,514	3.308 %	3 M $
Geode Capital Management LLC 2.108 %	2,002,394	2.108 %	2 M $
AQR Capital Management LLC 2.103 %	1,997,388	2.103 %	2 M $
STATE STREET CORPORATION 1.606 %	1,525,649	1.606 %	1 M $
Two Sigma Investments LP 1.328 %	1,261,229	1.328 %	1 M $

Assertio Holdings, Inc.

100 South Saunders Road Suite 300

60045, Lake Forest

http://www.assertiotx.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.03%	358B
MERCK & CO., INC.	+20.35%	322B
ABBVIE INC.	+8.20%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.32%	149B
AMGEN INC.	-6.17%	146B

Other Pharmaceuticals